Shanghai Fosun Pharmaceutical (Group) has announced that the novel coronavirus (2019-nCoV) antigen detection kit (Colloidal Gold) developed by Fosun Diagnostics, a subsidiary company of Fosun Pharma has received approval from the China's National Medical Products Administration (NMPA) for the commercial and clinical use of rapid antigen testing in COVID-19 screening.

The kit has adopted the in- vitro qualitative detection method of Nucleocapsid antigen in nasopharyngeal swab samples from patients with respiratory and fever-related symptoms within 7 days, quarantine observers, and other antigen detection needs. Fosun Diagnostics' Novel Coronavirus Antigen Detection Kit is equipped with high sensitivity and specificity, strong anti-interference ability and no cross-reactivity among viruses and bacteria. The kit is easy to use and quick to operate and deliver results in 15 minutes. It has a variety of reagents to meet various testing needs at point of demand whenever required.

Lately, the State Council's of China under the Joint Prevention & Control for novel coronavirus pneumonia has decided to include antigen detection as a key supplement to nucleic acid detection under the "New Coronavirus Antigen Detection Application Plan (Pilot Trial)". Fosun Diagnostics' Novel Coronavirus Antigen Detection Kit will contribute and continue serving the needs of pandemic prevention and control upon its recent approval.